#1
#1 out of 136.23%
health2h ago
Ozempic-style drugs linked to major slowdown in cancer spread, new study finds
- New study links GLP-1 weight-loss drugs to slower cancer progression in several obesity-related cancers.
- Study followed 12,112 patients and compared GLP-1 drugs with DPP-4 inhibitors.
- GLP-1 users had lower progression to stage 4 cancer for four solid tumor types, especially NSCLC and breast cancer.
- Researchers caution the findings are not proof of causation due to the observational design.
- Tumors with higher GLP-1 receptor levels showed better survival outcomes in the study.
- Researchers call for randomized trials to confirm how GLP-1 pathways affect cancer growth.
- Adverse side effects were similar between GLP-1 and gliptin groups in the study.
- Study authors note potential confounders like weight loss and metabolic changes could influence results.
- The research was presented at a major medical conference and not yet peer-reviewed.
- The report highlights GLP-1 pathways may directly influence cancer growth or spread.
Vote 0